




SETTING UP EXTRACTABLE STUDIES DO'S AND DON'TS

PDA TRAINING COURSE
EXTRACTABLES – LEACHABLES

BASEL
27 – 28 FEBRUARY 2020


Dr. Piet Christiaens

Extractables and Leachables



Extractables and Leachables

What **DOES** come out (from the material) in the **drug product**?




These compounds do **not** leach in the drug product




Extractables and Leachables

What **DOES** come out (from the material) in the **drug product**?



Leachables!




= screening
directly in drug
product

Extractables and Leachables




Drug product




Screening



**Compatible
with drug
product?**



Interference?




Threshold?

Extractables and Leachables




Drug product




Screening



**Compatible
with drug
product?**



Interference?



Threshold?



THE ANSWER: YOU NEED EXTRACTABLES DATA



What is the PURPOSE of an extraction study?

- Material characterization of the packaging components
- “Impurities profiling” of the materials
 - Identify as many compounds as possible
 - Identify “bad actors” in the materials
- Early risk evaluation: potential *patient exposure* to chemical entities
- Allows to establish leachables – extractable *correlations*
- In certain cases (more applicable to OINDP): Facilitates extractable specifications of *acceptance criteria*.
- Identify compounds that may need to be monitored as leachable
 - Toxicity
 - Concentration in the materials
 - Risk for migration

USP <1663> Monograph

“Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems”

This is an **INFORMAL** monograph

PQRI – Parenteral & Ophthalmic Drug Products
Product Quality Research Institute

Best Demonstrated Practice Recommendations: **Chemistry & Toxicology**

This is a **RECOMMENDATION**

REMARK: In Some Cases, Reference to the ISO 10993-12 (Medical Devices) can be Made to Determine the Extraction Conditions prior to Analysis.

These two documents are either **INFORMAL** or **RECOMMENDATIONS**

Allow flexibility in design


What is the *intent*? => **Strategy** of testing

How to design the study for the envisioned intent? => **Tactics**


However, justification is needed!

Both **identifying the necessity** for an extraction study, as well as **justifying the design**, is the responsibility of the holder of the NDA.

1. **LOW** Nr of extractables



2. **HIGH** Nr of extractables



HOW CAN THIS BE HARMONIZED?



Useful documentation prior to E-study

GENERAL INFORMATION

Product Name, Product N^o, Type, Manufacturer, Physical properties...

CERTIFICATES of compendial tests

USP<381>, USP <87>, USP<88>, EP 3.2.9, JP<49>, ISO 8871

INGREDIENTS OF RUBBER/PLASTIC

Very useful information, but this will not tell the complete E-story!!

EXTRACTABLES DATA FROM SUPPLIER

Highest Level of information ! Check relevancy of technical and testing conditions!!

VARIABLES that may/will have an impact on the study design of an extractables study

- The **classification & specific requirements** per drug product
 - Table 1 in FDA C/C-Guidance (1999)
 - Decision tree in the EMA-Guideline (2005)
- The **composition of the DP**, in contact with the C/C system
- The **type of contact** between the DP and the C/C system
 - Primary packaging
 - Secondary packaging (e.g. needle shield, label,...)
- The **types of materials** used in the manufacture of the C/C
 - E.g. rubber versus polyolefin for BFS
- The **knowledge on the composition** of materials (from vendor)
 - Additives, catalysts, oligomers, colorants,...
- The **use of the data**
 - Only for this particular application, or also for other DP?
- Packaging versus Manufacturing Equipment
 - **Dedicated session**



Extraction Solvents



Polarity,...

ACIDIC

ALKALINE



NEUTRAL
pH




Extraction conditions



Time & Temperature



autoclave



Reflux



Incubation (shaking)



Extraction ratio



Guidelines



Filling volume




SELECT WORST CASE CONDITIONS REPRESENTATIVE FOR FINAL APPLICATION

Chemical Nature of the Extracting Medium

If: PURPOSE: simulating worst case EXT-profile

- Look for Similar or Greater Extraction Propensity
- That gives Similar Qualitative and Quantitative EXT-profile
- **Use Drug Product Formulation**
 - May be complex or impractical
- **DPV/Placebo can be an Alternative**
 - REMARK: Extraction at High T with DP/DPV may lead to degradation (eg Polysorbate)





Extraction Solvents

Perform E-study in Drug Product (Vehicle), suggested in:

FDA-Container/Closure Guidance (1999), (eg parenteral/Ophthalmic)

- If the extraction properties of the drug product vehicle may reasonably be expected to differ from that of water (e.g., due to high or low pH or due to a solubilizing excipient), then drug product should be used as the extracting medium.

EMA-Guideline - immediate packaging (2005)

- stress conditions to increase the rate of extraction. The solvent used for extraction should have the
- same propensity to extract substances as the active substance/dosage form as appropriate. In the case of medicinal products the preferred solvent would be the medicinal product or placebo vehicle. The

ADVANTAGE: simulation of extractables behaviour in DP(V): same extraction propensity!

DISADVANTAGE:

Risk of missing the presence of compounds

- *Matrix interference of DP(V) (see previous slide)*


Risk of misinterpretation of analytical data

- *DP(V) Matrix degradant may be misinterpreted as extractable!*

Risk of underestimating the concentration of compounds

- *Extraction conditions – may potentially be too mild*

- *Difficult to select the right set of extraction conditions (e.g. Extraction time, temperature!)*



“USP <1663>: GENERATING THE EXTRACT

Chemical Nature of the Extracting Medium –

REMARKS WHEN CONSIDERING SELECTING DP/DPV

BETTER ALTERNATIVE:

SCREENING LEACHABLE STUDY

- *Use DP in the final Container/Closure System, stored in Stability*
- *Consider it as an extra “Solvent” in your Extractables Assessment*
- *Use same **Screening Methodologies** as you would do in an EXT Study*
- *This accounts for*
 - **Unexpected Leachables** (due to ageing of Material, Hydrolysis, Oxidation, **Migrants** from Sec, Tertiary Packaging...)
 - **Reactive Leachables** (eg with API, other ingredients...)
 - **Accurate Prediction** of the Nature of the Leachables, and their Expected Levels
 - *However:*
 - *Typically **not an End Point** in the Evaluation*
 - *Only a “**One Point Assessment**”*
 - ***Not all DP** are Amenable to Screening*

“USP <1663>: GENERATING THE EXTRACT

Chemical Nature of the Extracting Medium

If: PURPOSE: simulating worst case EXT-profile

If an Extraction Study needs a Simulating Solvent

Establish and Justify Composition of Simulating Solvent

Evaluate the PCHEM Properties of the Drug Product

pH

Polarity (Polar, versus Non-Polar, or Intermediate Polarity)

Stabilizers

Solubilizing Agents

Buffers

Lipid containing solutions

Biotech (proteins, peptides, blood derived products)

Chelating Agent

...

**REMARK: FOR EXTRACTION STUDIES: NOT IDEAL TO ONLY TAKE 1 EXTRACTION SOLVENT
COULD BE CONSIDERED IF THE PURPOSE IS TO PERFORM A SIMULATION STUDY**

“USP <1663>: GENERATING THE EXTRACT

Chemical Nature of the Extracting Medium

If: PURPOSE: simulating worst case EXT-profile

If an Extraction Study needs MULTIPLE Simulating Solvents

*Each Addressing 1 “Mechanism” that is relevant to the Drug Product
Is Consistent with the Industry “Best Practices” for High Risk Dosage
Forms.*

Also in Line with PQRI-Approach (see next slides)

REMARK: PQRI: proteins may be more efficient in solubilizing leachables due to abundance of both hydrophilic and hydrophobic sites*

In this case, an approach with multiple simulating solvents may be warranted.

* PQRI –PODP L/E Work Group: Outcomes and Practical Applications, D, Paskiet, Presentation at PEPTALK, 2016

“USP <1663>: GENERATING THE EXTRACT

Chemical Nature of the Extracting Medium

If: PURPOSE: Material Characterization (not a worst case EXT profile)

Use POWERFUL extraction Solvents

GOAL: to have an Efficient Quantitative & Qualitative Extraction

Powerful Extraction Solvents

Softening

Swelling

Dissolving

EXAMPLES OF POWERFUL SOLVENTS:


Dichloromethane, Hexane, Isopropanol, Ethanol ...

Selection will also depend upon the Material




Example: *Extraction of a rubber component*
GC/MS Semi-Volatile Organic Compound "Profile"


pH 2,5




pH 9,5




UPW/IPA 50/50



IPA



HEXANE



IS: Internal Standard for GC/MS

*: Internal Standard for LC/MS (not used in this GC/MS evaluation)

REMARK: Notice the Substantial "Visual" Difference in Extraction Profiles for the Different Extraction Solvents!



- PODP best demonstrated practice **recommendations**

UPW pH 2.5	UPW pH 9.5	UPW/IPA (50/50)	IPA	Hexane
Acid extractables	Alcalic extractables	Intermediate polarity	→	Non-polar

SIMULATION

MATERIAL
CHARACTERIZATION
&
SIMULATION
(NON AQUEUOUS DP)

Recommendations:

It is not mandatory to always include these 5 solvents



The solvents should be adjusted to the physico chemical properties of the DP

Justifications!!

Mechanism of Extraction – Extraction Technique

Reflux or Soxhlet Extractions

- Similar Extraction yields
- Reflux has shown - in limited cases - to introduce artefacts in extraction profile
 - Degradation of extractables during Reflux could occur
- Soxhlet has more practical implications
 - Takes longer (24h) to have the same extraction yields as reflux (8h)
 - Safety implications in Lab (24h extraction)
 - Less practical for solvents with high boiling points
 - Less practical for aqueous extraction vehicles
 - Not to be used when *pH adjusted solvents or mixtures (e.g. IPA/UPW)* are used



Sonication

- **Less exhaustive** than reflux & soxhlet (PQRI)
- However, it may be **less detrimental to certain materials**
- Often used as the extraction technique for **labels**
 - Avoids desintegration of label, while extracting most relevant compounds
- Difficult to control (see USP<1663>)

Sealed vessel

- Closed vessel avoids loss of **VOLATILE Organic Compounds**
- Typically ISO 10993-12 Conditions can be Used (e.g. 50°C, 72h)
- In general, a **24h SV-extraction** at a temperature of **10°C below boiling** point is **equivalent in yields** to an **8h reflux** extraction

Headspace enrichment

- *Direct analysis of the material* using Headspace GC/MS
- Complete profile of **VOLATILE Organic Compounds**
- **Water soluble** Compounds are **better detected**
(often a problem for Headspace GC on aqueous extracts)

“In Situ” extraction

- Container is filled with extraction solution, capped with closure and incubated.
- Allows **“one sided extraction”**
 - Coated rubbers
 - Sealing discs for cartridges
 - Multi-layer foils
- Better simulation, less exhaustive



Extraction Conditions


Consideration for “In-Situ” Extractions:

- Static Extraction: Pharmaceutical Packaging
- Dynamic Conditions, often considered for Production Items
 - *Tubings*
 - *Filters*
 - *Pump systems (also for IV administrations)*
- Dynamic extraction is a better simulation if the contact between the components and the DP/DS is also dynamic,

USP<1663> “Generating the extract” section “Extraction time and temperature”

The combination of extraction time and temperature establishes the magnitude of

the driving force and the degree to which equilibrium is achieved



Time and temperature are closely linked to the extraction technique that is used






Extraction time and temperature


Typical temperature / time settings:

- Reflux with organic solvents:
 - Boiling temperature, 8 h
- Soxhlet with organic solvents:
 - Boiling temperature, 24 h
- Sonication:
 - Room temperature, ½ to 1h
- Sealed vessel and “*in situ*” extraction:
 - 50°C, 72 h (ISO 10993-12)
 - 24h below boiling point of extraction solvent = equivalent to 8h reflux
- Headspace enrichment:
 - 40 minutes, temperature is selected based on the type of material (from 70°C for LDPE up to 150° for rubbers / elastomeric material)
- Dynamic Extractions:
 - Extraction Conditions are determined based upon the conditions of use

Case study: impact of extraction time



Asymptotic extraction profile - exhaustive extractions:



PQRI-Example:

- Test article: sulphur cured elastomer
- Extraction: DCM – soxhlet

*CONCLUSION: Extraction conditions on the 'plateau'-regime (equilibrium)
= "MAXIMUM RISK"*



Extraction Stoichiometry

Stoichiometry: physical mass/surface area to volume

Can be based on

Known chemical ingredients in a component/material

Safety based thresholds for DP leachables

Known sensitivities of the analytical instrumentation

Stoichiometry can be manipulated to produce a more concentrated extract

REMARK: beware of solubility of extractables in extraction medium when “back extrapolating” to original ratio’s!

Physical state can be altered (cut, ground, altered in size...)

- Try to stay as close as possible to the ratio's of the actual use of the container
 - E.g. A rubber plunger for a 10 mL PFS could be extracted at a ratio of 1 plunger per 10 mL of solvent
- For raw materials, a reasonable, broadly accepted ratio is 1g/10mL
- For certain container closure systems (e.g. LVP), the final AET levels that may need to be considered may have an impact on the extraction ratio's!

Example

- For a 1 L bag (bag weighs 50g), Final AET in DP is at 1.5µg/L
- This means that for the extraction study, 1.5µg/Bag(50g) or 30µg/g needs to be attained
- With a ratio of 1bag in 1L, this AET cannot be attained
- Higher material-to-solvent ratios will need to be considered

What **CAN** come out of the **material**?

PACKAGING/MATERIAL



Extraction Solvents



Extraction conditions



Extraction ratio

ANALYSES OF THE EXTRACTS






IDENTIFICATION
IDENTIFICATION
IDENTIFICATION
IDENTIFICATION
IDENTIFICATION
IDENTIFICATION
IDENTIFICATION
IDENTIFICATION
IDENTIFICATION
IDENTIFICATION




A **broad identification** in “First Pass” extractable studies requires:

1. A compound specific detector: **Mass Spectrometry**
2. A **database** to allow Identification based upon Mass Spectra
 - Commercial Databases for GC/MS: NIST, WILEY
 - Customized Databases





Identification





Screening


Trying to identify every single peak in a chromatogram



IDENTIFICATION










Extract



Identification



Screening



Orthogonal techniques

VOC

HS-GC/MS
Screening

SVOC


GC/MS
Screening

NVOC

UPLC/MS
Screening



ICP/OES
ICP/MS





IC
GF-AAS
LC/UV ...

EXTRACTABLES PROFILE: Potentially Leaching Compounds of Concern

EXTRACTABLES


Identification

- Knowledge of material
- What **CAN** come out




Initial Toxicological Evaluation

Example:
Cramer + Derek Nexus
Toxicologist/ consultant
Select Targets



LEACHABLES

- What **DOES** come out in the drug product



Screening



Target

5. TIME FOR QUESTIONS

